Birgitta Versluijs

178 References 43. Varelias A, Gartlan KH, Kreijveld E, Ol- ver SD, Lor M, Kuns RD, et al. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury af- ter allogeneic stem cell transplantation. Blood. 2015;125(15):2435-44. 44. Ahya VN. Noninfectious Acute Lung Injury Syndromes Early After Hemato- poietic Stem Cell Transplantation. Clin Chest Med. 2017;38(4):595-606. 45. Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, et al. Randomized, double-blind, placebo- controlled trial of soluble tumor necro- sis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneu- monia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network pro- tocol. Biol Blood Marrow Transplant. 2014;20(6):858-64. 46. Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A syste- matic review. The Journal of heart and lung transplantation. 2017;36(9):921-33. 47. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, Azithromycin, and Montelukast Treat- ment for New-Onset Bronchiolitis Obli- terans Syndrome after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016;22(4):710-6. 9